Publications by authors named "P Hinterdorfer"

Epithelial cell adhesion molecule (EpCAM) fused to IgG, IgA and IgM Fc domains was expressed to create IgG, IgA and IgM-like structures as anti-cancer vaccines in Nicotiana tabacum. High-mannose glycan structures were generated by adding a C-terminal endoplasmic reticulum (ER) retention motif (KDEL) to the Fc domain (FcK) to produce EpCAM-Fc and EpCAM-FcK proteins in transgenic plants via Agrobacterium-mediated transformation. Cross-fertilization of EpCAM-Fc (FcK) transgenic plants with Joining chain (J-chain, J and JK) transgenic plants led to stable expression of large quaternary EpCAM-IgA Fc (EpCAM-A) and IgM-like (EpCAM-M) proteins.

View Article and Find Full Text PDF

Transgenic tobacco plant expressed EpCAM-Fc fusion proteins to induce in vivo immune responses producing anti-EpCAM antibodies inhibiting human colorectal cancer cell invasion and migration. Plant is emerging as a promising alternative to produce valuable immunotherapeutic vaccines. In this study, we examined the in vivo anti-cancer efficacy of epidermal cell adhesion molecule (EpCAM)-Fc and EpCAM-FcK fusion proteins produced in transgenic plants as colorectal cancer vaccine candidates.

View Article and Find Full Text PDF

Ultraviolet-C (UV-C) radiation and ozone gas are potential mechanisms employed to inactivate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), each exhibiting distinct molecular-level modalities of action. To elucidate these disparities and deepen our understanding, we delve into the intricacies of SARS-CoV-2 inactivation via UV-C and ozone gas treatments, exploring their distinct molecular-level impacts utilizing a suite of advanced techniques, including biological atomic force microscopy (Bio-AFM) and single virus force spectroscopy (SVFS). Whereas UV-C exhibited no perceivable alterations in virus size or surface topography, ozone gas treatment elucidated pronounced changes in both parameters, intensifying with prolonged exposure.

View Article and Find Full Text PDF
Article Synopsis
  • Traditional monoclonal antibodies like Trastuzumab have limitations when treating HER2-positive breast cancer, especially in resistant cases.
  • The study presents a plant-derived anti-HER2 antibody known as VHH-FcK, which shows strong binding dynamics and durability against HER2 on living cells.
  • In trials with immune-deficient mice, VHH-FcK demonstrated higher antitumor effectiveness, particularly against tumors that do not respond to Trastuzumab, indicating its potential as a new treatment option.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates producing therapeutic monoclonal antibodies (mAbs) in transgenic plants, highlighting benefits like large-scale production and reduced risk of animal contaminants.
  • It focuses on modifying the mAb SO57 using Fc-engineering with an ER-retention signal to improve its binding to the human neonatal Fc receptor (hFcRn), which influences the antibody's lifespan in circulation.
  • Results showed that engineered variants of mAbK SO57 maintained similar glycan structures and neutralizing activity against the rabies virus, indicating enhanced effectiveness without compromising their function.
View Article and Find Full Text PDF